Page last updated: 2024-08-23

paclitaxel and Jejunal Diseases

paclitaxel has been researched along with Jejunal Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hunter, N; Li, C; Mason, KA; Milas, L; Wallace, S	1

Other Studies

1 other study(ies) available for paclitaxel and Jejunal Diseases

Article	Year
Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3 Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Confidence Intervals; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Hair; Infusions, Intravenous; Jejunal Diseases; Mice; Mice, Inbred C3H; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Specific Pathogen-Free Organisms; Taxoids	2003

Article

Year

Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability.

International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3

Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Confidence Intervals; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Hair; Infusions, Intravenous; Jejunal Diseases; Mice; Mice, Inbred C3H; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Specific Pathogen-Free Organisms; Taxoids

2003